Straits Times Index
3,336.59 +13.21 (+0.40%) Nikkei
38,487.90 +433.77 (+1.14%) Hang Seng
18,079.61 -150.58 (-0.83%) FTSE 100
8,275.38 +44.33 (+0.54%) Bitcoin USD
67,736.07 +329.77 (+0.49%) CMC Crypto 200
1,426.38 -2.19 (-0.15%)
BRKR Sep 2024 100.000 call
| Previous close | 5.75 |
| Open | 5.75 |
| Bid | 4.80 |
| Ask | 5.30 |
| Strike | 100.00 |
| Expiry date | 2024-09-20 |
| Day's range | 5.75 - 5.75 |
| Contract range | N/A |
| Volume | |
| Open interest | 4 |
Business WireBruker Corporation to Present at Upcoming Investor Conferences
BILLERICA, Mass., May 31, 2024--Bruker Corporation (Nasdaq: BRKR) announced today it will present at the following conferences:
GlobeNewswireBiognosys Launches Spectronaut 19 and Presents Advances with Its Research Platforms at the ASMS 2024 Annual Conference
Spectronaut® by Biognosys DIA Proteomics Analysis Software Spectronaut® 19 offers significant improvements in identifications, candidate discovery, scalability for large-scale analysis, and support for novel workflowsNovel TrueDiscovery® P2 Plasma Enrichment method offers market-leading performance and superior economics for unbiased, deep plasma proteomicsNew TrueTarget® high-throughput LiP-MS workflow enables large-scale drug target deconvolution screening with improved target identificationDi
GlobeNewswireBiognosys launches groundbreaking P2 Plasma Enrichment technology for unbiased, deep plasma proteomics at ASMS 2024
Biognosys Newton, Massachusetts proteomics facility Mass spectrometry laboratory The proprietary P2 Plasma Enrichment method leverages a novel single-well, single particle-type enrichment method to achieve market-leading performance for unbiased, deep mass spectrometry-based plasma proteomics P2 now offers excellent quantitation and higher throughput for large-cohort biomarker or drug discovery studies, and clinical, epidemiological or population proteomics research P2 Plasma Enrichment is avail
